IKT-902

N/A

Report date: 2026/03/19 16:58:13

Base Information

Drug NameIKT-902
Drug Alias NameEpCAM-TEA-VVanti-CD3/anti-EpCAM bispecific T-cell engager (Icell Kealex)IKT-902
ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionEpithelial cell adhesion molecule modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3Epithelial cell adhesion molecule
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIcell Kealex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesIcell Kealex Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A